Efficacy evaluation and safety testing of infectious disease vaccines and therapeutic drugs
Southern Research, for which we are an agent, undertakes nonclinical efficacy evaluation studies of infectious disease vaccines and therapeutic drugs. They have established in vivo infection models for a variety of viruses and are capable of conducting tests at BSL2 or BSL3. In addition to efficacy evaluation, they also undertake nonclinical safety studies in accordance with GLP and immunogenicity tests (analysis of clinical samples) in accordance with GCLP.
For testing requests or inquiries regarding Southern Research, please feel free to contact the Lunapath Toxicological and Pathological Laboratory.
About Southern Research
Southern Research features:
Broad pathogen expertise (influenza, COVID-19, monkeypox, flaviviruses including chikungunya, dengue, and Zika)
Small animal (rats, mice, hamsters, ferrets, etc.) ~ Primate (NHPs) infectious disease models
Extensive experience in handling Tier 1 Select Agents (e.g. MPOX)
Research conducted in compliance with FDA animal regulations
Contracted Test Items
In vivo efficacy evaluation test:
Infectious disease model
SARS-COV-2
Influenza A
Respiratory Syncytial Virus (RSV)
Vaccinia
Herpes Simplex Virus (HSV-1)
West Nile Virus
Zika virus, Yellow fever
Chikungunya virus
Hepatitis B virus (HBV)
Dengue virus (DENV-2 or 1)
Monkeypox
SIV, SHIV, etc.
In vitro antiviral test:
CPE assay
immunostaining
GFP reporter assay, etc.
Non-clinical safety studies (GLP) :
General toxicity tests (small and large animals)
Biodistribution and pharmacokinetic studies
Immunogenicity testing
Neurotoxicity Testing
Clinical trial sample analysis (GCLP) :
Vaccine Immunogenicity Studies
Microneutralization Assay (MA )
Focus Reduction Neutralization Test (FRNT)
Infection prevention effect (viral load measurement)
PCR
RT-PCR
TCID50
Facility Overview
Southern Research's testing facility is located in Birmingham, Alabama, USA. Our state-of-the-art BSL3 facility also provides GLP-compliant non-clinical safety testing.
